Replies to post #486513 on NorthWest Biotherapeutics Inc (NWBO)

[CrashOverride]

These costs are still reimbursable by NHS under NICE guidelines.

£200,000 / 5Y survival = £40,000 cost per QALY

The majority of cancer drugs (7/11) were valued above $42,857 but less than $71,429 (£50,000), a second higher threshold for end-of-life care and rare conditions that applies to most of these cancer therapies. Only one drug, enzalutamide, was not recommended for use in England as it was definitively above the end-of-life threshold at $80,240 and had questionable certainty for overall survival.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788430/

So we are well within the acceptable range for NICE approval given end of life and rare diseases have a higher QALY threshold than then normal range of £20,000 - £30,000. Keytruda was approved at £59,406 which we are below significantly. So we do not need to be concerned about upsetting NICE by asking for reimbursement without Flaskworks in place.